Unknown

Dataset Information

Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma.


ABSTRACT: Glioma is a malignant tumor with the highest incidence among all brain tumors (about 46% of intracranial tumors) and is the most common primary intracranial tumor. Among them, glioblastoma (GBM) is highly malignant and is one of the three refractory tumors with the highest mortality rate in the world. The survival time from glioblastoma diagnosis to death is only 14-16 months for patients with standard treatment such as surgery plus radiotherapy and chemotherapy. Due to its high malignancy and poor prognosis, in-depth studies have been conducted to explore effective therapeutic strategies for glioblastoma. In addition to the conventional surgery, radiotherapy, and chemotherapy, the glioblastoma treatments also include targeted therapy, immunotherapy, and electric field treatment. However,

SUBMITTER: Wu H 

PROVIDER: S-EPMC8446212 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature